ARTELO BIOSCIENCES, INC.
ARTLBusiness Summary
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system (ECS) 1. The company's core business model revolves around the research, development, and eventual commercialization of ethical pharmaceutical products that modulate lipid signaling. Revenue generation is currently limited, with the company not having generated any revenue from product sales to date and not expecting to in the near future 2. The primary customer segments, once products are approved, would be patients via prescription or physician orders 3. The company plans to retain rights to internally develop and commercialize products but may seek collaborations with biopharmaceutical partners to maximize stockholder value 4.
The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid (CB) agonist targeting CB1 and CB2 peripheral receptors, which is being developed as a potential treatment for cancer-related anorexia 5. This program is currently in a Phase 1b/2a trial, titled the Cancer Appetite Recovery Study (CAReS) 6. Interim analysis from the Phase 2a CAReS trial showed patients receiving ART27.13 demonstrated a mean weight gain of over 6% compared to a 5% loss in the placebo group, with a safety profile similar to Phase 1b despite higher doses 7. There is currently no FDA-approved treatment for cancer anorexia cachexia syndrome 8. The estimated global market size for cancer anorexia cachexia syndrome is over $3 billion 9.
Another key product candidate is ART26.12, a small molecule from the company's library of fatty acid binding protein (FABP) inhibitors, specifically targeting FABP5 10. ART26.12 is being developed to treat chemotherapy-induced peripheral neuropathy (CIPN) and has completed enrollment for a Phase 1 clinical trial in healthy subjects 11. Favorable results from this first-in-human study were announced in June 2025, showing mild, transient, and self-resolving adverse events, no drug-related adverse events in the blinded dataset, and dose-dependent, linear absorption across the evaluated range 12. ART26.12 also has potential broad applications as a cancer therapeutic, for dermatologic conditions like psoriasis, for pain and inflammation, and in anxiety-related disorders such as post-traumatic stress disorder (PTSD) 13. The estimated global market sizes for its potential indications are over $2 billion for CIPN, approximately $13 billion for prostate cancer, approximately $33 billion for breast cancer, $31 billion for psoriasis, and approximately $13 billion for PTSD 14.
The third product candidate, ART12.11, is a wholly-owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) 15. ART12.11 has shown improved pharmacokinetics and efficacy compared to other forms of CBD in nonclinical studies, with enhanced pharmaceutical properties including physicochemical, pharmacokinetic, and pharmacodynamic advantages 16. The U.S. composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has been granted or validated in 21 additional countries 17. The company plans to develop ART12.11 for multiple potential indications where CBD has shown activity, such as anxiety disorders including PTSD, depression, epilepsy, and insomnia 18. The estimated global market sizes for anxiety disorders and PTSD are both over $13 billion 19.
For the fiscal year ended December 31, 2025, the company reported total operating expenses of $11.404 million 20, an increase from $10.108 million in 2024 21. This resulted in a loss from operations of $11.404 million 22. After accounting for other income (expense) of $(1.475) million 23, the net loss for the period was $12.879 million 24, compared to a net loss of $9.826 million in 2024 25. Basic and diluted loss per common share was $(12.52) 26 for 2025, compared to $(18.30) 27 for 2024. Cash used in operating activities was $8.520 million 28 in 2025, an increase from $8.350 million 29 in 2024. As of December 31, 2025, cash and cash equivalents were $0.6 million 30, and the company had a negative working capital of $3.349 million 31. Total liabilities were $4.073 million 32, and total stockholders' deficit was $(1.272) million 33.
Year-over-year, operating expenses increased by $1.296 million 34, primarily due to increased professional fees related to financing activities and higher stock-based compensation, partially offset by a decrease in research and development activities 35. General and administrative expenses rose to $5.981 million 36 in 2025 from $4.115 million 37 in 2024, an increase of $1.866 million 38. Research and development expenses decreased to $5.423 million 39 in 2025 from $5.993 million 40 in 2024, a decrease of $0.570 million 41. The net loss widened by $3.053 million 42 from 2024 to 2025. Cash used in investing activities shifted from a provision of $7.769 million 43 in 2024 to a use of $0.062 million 44 in 2025, primarily due to the purchase and subsequent sale of Solana cryptocurrency in 2025, contrasting with dispositions of trading marketable securities in 2024 45. Cash provided by financing activities significantly increased to $6.867 million 46 in 2025 from $0.112 million 47 in 2024, driven by net proceeds from common share issuance of $6.151 million 48, convertible notes of $0.419 million 49, and warrant exercises of $0.132 million 50.
Significant operational developments during the period include the announcement of favorable interim results from the Phase 2a CAReS trial for ART27.13 on September 3, 2025, showing compelling increases in mean body weight of 6.38% in the treatment group compared to a -5.42% loss in the placebo group after 12 weeks of treatment in titrated patients 51. The company also announced favorable results from its first-in-human study evaluating ART26.12 in June 2025, demonstrating safety, tolerability, and dose-dependent, linear absorption in healthy volunteers 52. In terms of financing, the company engaged in several equity and debt offerings, including a private placement in June 2025 raising $1.079 million net proceeds 53, an At-The-Market Offering Agreement in July 2025 under which $0.442 million net proceeds were generated 54, and two underwritten offerings in September 2025 yielding net proceeds of $2.690 million 55 and $1.760 million 56 respectively. The company also issued unsecured convertible notes with gross proceeds of $0.900 million in May 2025 57, which were subsequently converted into new convertible notes and warrants in October 2025 58.
Business Outlook
The company explicitly states that it has not generated any revenue to date and does not expect to generate any revenue from product sales or other sources for at least the next several years, if at all 59. It anticipates incurring significant operating losses for the foreseeable future until the development and approval of one of its product candidates is complete 60. The company expects to continue funding its operations primarily through additional capital raises 61.
A major growth area for the company is the continued development of ART27.13 for cancer-related anorexia, which is currently in a Phase 1b/2a trial 62. Interim analysis from the Phase 2a CAReS trial has shown promising results, with patients receiving ART27.13 demonstrating a mean weight gain of over 6% compared to a 5% loss in the placebo group 63. The company has received regulatory approval in the UK, Ireland, and Norway to increase the daily dose up to 1,300 micrograms and to enroll 40 evaluable patients into the Phase 2a stage with a 3:1 randomization of ART27.13 to placebo 64. The estimated global market size for cancer anorexia cachexia syndrome is over $3 billion 65, representing a significant market opportunity if ART27.13 achieves regulatory approval.
Another significant growth vector is ART26.12, a FABP5 inhibitor, with an initial indication targeting chemotherapy-induced peripheral neuropathy (CIPN) 66. The company completed enrollment for a Phase 1 clinical trial in healthy subjects in April 2025 and announced favorable first-in-human study results in June 2025, confirming safety, tolerability, and dose-dependent, linear absorption 67. Beyond CIPN, ART26.12 has potential applications as a cancer therapeutic, for dermatologic conditions like psoriasis, for pain and inflammation, and in anxiety-related disorders such as PTSD 68. The estimated global market for CIPN is over $2 billion, for prostate cancer approximately $13 billion, for breast cancer approximately $33 billion, for psoriasis $31 billion, and for PTSD approximately $13 billion 69. The company has also been awarded a research grant in Canada to expand its research into FABP5 inhibition for anxiety disorders 70.
The company's third product candidate, ART12.11, a synthetic CBD cocrystal, is targeted for development in anxiety disorders and rare/orphan diseases 71. Preclinical studies have shown ART12.11 to have better pharmacokinetics and improved efficacy compared to other forms of CBD, with a U.S. composition of matter patent enforceable until December 10, 2038 72. The estimated global market sizes for anxiety disorders and PTSD are both over $13 billion 73.
Operationally, the company expects its expenses and capital requirements to increase substantially as it continues research and development activities, maintains and expands its intellectual property portfolio, implements operational, financial, and management information systems, and attracts and retains additional personnel 74. The company is currently receiving R&D tax credits from the UK, but the value of these credits is expected to decrease due to legislative changes and an increase in R&D activities in the U.S., potentially reducing payable credits to a lower rate of 10% 75. Furthermore, increased compliance activity by UK tax authorities may delay R&D credit payments by 6-12 months 76.
Planned capital allocation includes continued substantial investment in research and development activities 77. The company intends to obtain additional capital through public or private equity offerings, debt financings, credit or loan facilities, or a combination of these sources 78. A subsequent event in January 2026 involved entering into an Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5, providing the company with the right, but not the obligation, to sell up to $25 million in common stock, with an option to increase by an additional $25 million 79. In consideration, the company issued 106,026 shares of Common Stock and 186,372 pre-funded warrants with an aggregate value of $500,000 80. The company does not plan to declare or pay any dividends to stockholders in the near future, intending to reinvest earnings, if any, into business operations 81.
Structural headwinds and execution risks management explicitly flagged include the need to raise additional financing, with no assurance of availability on acceptable terms 82. The company's financial condition raises substantial doubt about its ability to continue as a going concern, with cash and cash equivalents of $0.6 million and negative working capital of $3.3 million as of December 31, 2025 83. Delays in clinical trials, potential adverse side effects of product candidates, and the inherent uncertainty of clinical drug development are also significant risks 84. The company's reliance on third parties for preclinical research, clinical trials, and manufacturing supply chains poses risks if these parties do not perform satisfactorily or meet deadlines 85. Geopolitical tensions, including conflicts in Eastern Europe and the Middle East, and trade policies, particularly with China, may disrupt investment, supply chains, and the economy generally, adversely affecting clinical trials and potential partnerships 86. Regulatory changes, such as the Inflation Reduction Act of 2022 (IRA), are expected to have far-reaching, long-term, and adverse effects on the pharmaceutical and biotech industry, potentially discouraging investment in small-molecule drug innovation and impacting patent litigation and market entry opportunities 87. The recent U.S. Supreme Court decision overturning the Chevron doctrine may also invite more lawsuits against the FDA, leading to uncertainties and potential delays in regulatory approvals 88.
Risk Factors
The company faces material risks including its ability to raise additional financing, as evidenced by its cash and cash equivalents of $0.6 million 89 and negative working capital of $3.3 million 90 as of December 31, 2025, which raises substantial doubt about its ability to continue as a going concern 91. Operational risks include potential delays or termination of clinical trials due to unforeseen safety issues, lack of efficacy, or failure to meet regulatory requirements 92. The company is highly dependent on third parties for preclinical research, clinical trials, and manufacturing, and their unsatisfactory performance could significantly impact product development timelines 93. Geopolitical tensions and trade policies, particularly with China, could disrupt supply chains and investment 94. Regulatory changes, such as the Inflation Reduction Act of 2022, are expected to have adverse effects on the pharmaceutical industry, potentially discouraging investment in small-molecule drug development and impacting market entry opportunities 95. The recent overturning of the Chevron doctrine by the U.S. Supreme Court may lead to increased litigation against the FDA, creating regulatory uncertainty and potential delays in drug approvals 96. Furthermore, the value of UK R&D tax credits is expected to decrease, and payments may be delayed by 6-12 months due to increased compliance activity 97.
Management Priorities
Management's overall tone emphasizes the company's focus as a clinical-stage biopharmaceutical entity dedicated to developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system. They highlight the progress of their product candidates, ART27.13 in Phase 1b/2a for cancer-related anorexia, with interim results showing a mean weight gain of over 6% 98 in treated patients, and ART26.12, a FABP5 inhibitor, which has completed a Phase 1 study with favorable safety and pharmacokinetic results 99. A key strategic priority is to continue funding operations primarily through additional capital raises, as the company has not generated any revenue to date and does not expect to in the near future 100. Management also stresses the importance of maintaining and expanding its intellectual property portfolio, as demonstrated by the ART12.11 synthetic CBD cocrystal with a U.S. patent enforceable until December 10, 2038 101. Another strategic priority is to leverage existing preclinical and clinical research from in-licensed programs to accelerate development and commercialization timelines across the portfolio 102.
View Source Annual Report on SEC.gov ↗
References
- [1] Item 1, Business — Corporate Overview
- [2] Item 7, MD&A — Revenue
- [3] Item 1, Business — Corporate Overview
- [4] Item 1, Business — Corporate Overview
- [5] Item 1, Business — Corporate Overview
- [6] Item 1, Business — Corporate Overview
- [7] Item 1, Business — Corporate Overview
- [8] Item 1, Business — Corporate Overview
- [9] Item 1, Business — Product Candidate Pipeline
- [10] Item 1, Business — Corporate Overview
- [11] Item 1, Business — Corporate Overview
- [12] Item 1, Business — Corporate Overview
- [13] Item 1, Business — Corporate Overview
- [14] Item 1, Business — Product Candidate Pipeline
- [15] Item 1, Business — Corporate Overview
- [16] Item 1, Business — Corporate Overview
- [17] Item 1, Business — Corporate Overview
- [18] Item 1, Business — Corporate Overview
- [19] Item 1, Business — Product Candidate Pipeline
- [20] Item 7, MD&A — Results of Operations
- [21] Item 7, MD&A — Results of Operations
- [22] Item 7, MD&A — Results of Operations
- [23] Item 7, MD&A — Results of Operations
- [24] Item 7, MD&A — Results of Operations
- [25] Item 7, MD&A — Results of Operations
- [26] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [27] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [28] Item 7, MD&A — Historical Cash Flows
- [29] Item 7, MD&A — Historical Cash Flows
- [30] Item 7, MD&A — Liquidity and Capital Resources
- [31] Item 7, MD&A — Working Capital
- [32] Item 8, Consolidated Balance Sheets
- [33] Item 8, Consolidated Balance Sheets
- [34] Item 7, MD&A — Results of Operations
- [35] Item 7, MD&A — Results of Operations
- [36] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [37] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [38] Item 7, MD&A — Results of Operations
- [39] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [40] Item 8, Consolidated Statements of Operations and Comprehensive Loss
- [41] Item 7, MD&A — Results of Operations
- [42] Item 7, MD&A — Results of Operations
- [43] Item 7, MD&A — Historical Cash Flows
- [44] Item 7, MD&A — Historical Cash Flows
- [45] Item 7, MD&A — Cash Flows from Investing Activities
- [46] Item 7, MD&A — Historical Cash Flows
- [47] Item 7, MD&A — Historical Cash Flows
- [48] Item 7, MD&A — Cash Flows from Financing Activities
- [49] Item 7, MD&A — Cash Flows from Financing Activities
- [50] Item 7, MD&A — Cash Flows from Financing Activities
- [51] Item 1, Business — Corporate Overview
- [52] Item 1, Business — Corporate Overview
- [53] Item 7, MD&A — Sources of Liquidity
- [54] Item 7, MD&A — Sources of Liquidity
- [55] Item 7, MD&A — Sources of Liquidity
- [56] Item 7, MD&A — Sources of Liquidity
- [57] Item 7, MD&A — Sources of Liquidity
- [58] Item 7, MD&A — Sources of Liquidity
- [59] Item 7, MD&A — Revenue
- [60] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [61] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [62] Item 1, Business — Corporate Overview
- [63] Item 1, Business — Corporate Overview
- [64] Item 1, Business — Corporate Overview
- [65] Item 1, Business — Product Candidate Pipeline
- [66] Item 1, Business — Corporate Overview
- [67] Item 1, Business — Corporate Overview
- [68] Item 1, Business — Corporate Overview
- [69] Item 1, Business — Product Candidate Pipeline
- [70] Item 1, Business — Corporate Overview
- [71] Item 1, Business — Corporate Overview
- [72] Item 1, Business — Corporate Overview
- [73] Item 1, Business — Product Candidate Pipeline
- [74] Item 7, MD&A — Funding Requirements
- [75] Item 1A, Risk Factors — The Company is currently receiving Research and Development ("R&D") tax credits from the UK in connection with its activities in the UK. The value of these will likely decrease and there is an increased risk payments may be significantly delayed.
- [76] Item 1A, Risk Factors — The Company is currently receiving Research and Development ("R&D") tax credits from the UK in connection with its activities in the UK. The value of these will likely decrease and there is an increased risk payments may be significantly delayed.
- [77] Item 7, MD&A — Funding Requirements
- [78] Item 7, MD&A — Funding Requirements
- [79] Item 12, Subsequent Events
- [80] Item 12, Subsequent Events
- [81] Item 5, Dividend Policy
- [82] Item 1A, Risk Factors — The Company will need to raise additional financing to support our business objectives. The Company cannot be sure the Company will be able to obtain additional financing on terms favorable to us when needed, or at all. If the Company is unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.
- [83] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [84] Item 1A, Risk Factors — Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and clinical trials may not be predictive of future clinical trial results, and our clinical trials may fail to adequately demonstrate substantial evidence of safety and efficacy of our product candidates.
- [85] Item 1A, Risk Factors — The Company will need to rely on third parties to conduct our preclinical research and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such research or trials.
- [86] Item 1A, Risk Factors — Geopolitical tensions, including the war in Ukraine and the Israel-Hamas war or other regional conflicts may disrupt investment in our business, supply chains carrying required materials and the movement of people globally. Such disruptions may adversely affect our clinical trials, scope of potential partners and our business generally.
- [87] Item 1A, Risk Factors — Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
- [88] Item 1A, Risk Factors — Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.
- [89] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [90] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [91] Item 1A, Risk Factors — Our financial condition raises substantial doubt as to our ability to continue as a going concern.
- [92] Item 1A, Risk Factors — Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and clinical trials may not be predictive of future clinical trial results, and our clinical trials may fail to adequately demonstrate substantial evidence of safety and efficacy of our product candidates.
- [93] Item 1A, Risk Factors — The Company will need to rely on third parties to conduct our preclinical research and clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such research or trials.
- [94] Item 1A, Risk Factors — Geopolitical tensions, including the war in Ukraine and the Israel-Hamas war or other regional conflicts may disrupt investment in our business, supply chains carrying required materials and the movement of people globally. Such disruptions may adversely affect our clinical trials, scope of potential partners and our business generally.
- [95] Item 1A, Risk Factors — Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
- [96] Item 1A, Risk Factors — Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.
- [97] Item 1A, Risk Factors — The Company is currently receiving Research and Development ("R&D") tax credits from the UK in connection with its activities in the UK. The value of these will likely decrease and there is an increased risk payments may be significantly delayed.
- [98] Item 1, Business — Corporate Overview
- [99] Item 1, Business — Corporate Overview
- [100] Item 7, MD&A — Revenue
- [101] Item 1, Business — Corporate Overview
- [102] Item 1, Business — Scientific Approach
Analysis on 5/22/2026